BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15917949)

  • 1. Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.
    Park SI; Felipe CR; Machado PG; Garcia R; Skerjanec A; Schmouder R; Tedesco-Silva H; Medina-Pestana JO
    Braz J Med Biol Res; 2005 May; 38(5):683-94. PubMed ID: 15917949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.
    Kovarik JM; Schmouder R; Barilla D; Riviere GJ; Wang Y; Hunt T
    J Clin Pharmacol; 2004 May; 44(5):532-7. PubMed ID: 15102874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.
    Tedesco-Silva H; Mourad G; Kahan BD; Boira JG; Weimar W; Mulgaonkar S; Nashan B; Madsen S; Charpentier B; Pellet P; Vanrenterghem Y
    Transplantation; 2005 Jun; 79(11):1553-60. PubMed ID: 15940045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T- and B-cells in cynomolgus monkeys when given alone, with Cyclosporine Neoral or with RAD.
    Quesniaux VF; Menninger K; Kunkler A; Vedrine C; Bernhard M; Hedinger R; Kraus G; Schuurman HJ
    Transpl Immunol; 2000 Nov; 8(3):177-87. PubMed ID: 11147698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
    Kahan BD; Karlix JL; Ferguson RM; Leichtman AB; Mulgaonkar S; Gonwa TA; Skerjanec A; Schmouder RL; Chodoff L
    Transplantation; 2003 Oct; 76(7):1079-84. PubMed ID: 14557756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD.
    Schuurman HJ; Menninger K; Audet M; Kunkler A; Maurer C; Vedrine C; Bernhard M; Gaschen L; Brinkmann V; Quesniaux V
    Transplantation; 2002 Oct; 74(7):951-60. PubMed ID: 12394836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine.
    Troncoso P; Stepkowski SM; Wang ME; Qu X; Chueh SC; Clark J; Kahan BD
    Transplantation; 1999 Jan; 67(1):145-51. PubMed ID: 9921811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction.
    Kovarik JM; Schmouder RL; Barilla D; Büche M; Rouilly M; Berthier S; Wang Y; Van Saders C; Mayer T; Gottlieb AB
    Ann Pharmacother; 2004; 38(7-8):1153-8. PubMed ID: 15138297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined FTY720/cyclosporine A treatment promotes graft survival and lowers the peripheral lymphocyte count in DA to lewis heart and skin transplantation models.
    Nikolova Z; Hof A; Baumlin Y; Hof RP
    Transpl Immunol; 2001 Feb; 8(4):267-77. PubMed ID: 11316070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation.
    Tedesco-Silva H; Pescovitz MD; Cibrik D; Rees MA; Mulgaonkar S; Kahan BD; Gugliuzza KK; Rajagopalan PR; Esmeraldo Rde M; Lord H; Salvadori M; Slade JM;
    Transplantation; 2006 Dec; 82(12):1689-97. PubMed ID: 17198261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients.
    Budde K; Schmouder RL; Brunkhorst R; Nashan B; Lücker PW; Mayer T; Choudhury S; Skerjanec A; Kraus G; Neumayer HH
    J Am Soc Nephrol; 2002 Apr; 13(4):1073-1083. PubMed ID: 11912269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel immunosuppressant, FTY720, induces peripheral lymphodepletion of both T- and B cells and immunosuppression in baboons.
    Quesniaux V; Fullard L; Arendse H; Davison G; Markgraaff N; Auer R; Ehrhart F; Kraus G; Schuurman HJ
    Transpl Immunol; 1999 Sep; 7(3):149-57. PubMed ID: 10608298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive drugs in paediatric liver transplantation.
    van Mourik ID; Kelly DA
    Paediatr Drugs; 2001; 3(1):43-60. PubMed ID: 11220404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients.
    Budde K; L Schmouder R; Nashan B; Brunkhorst R; W Lücker P; Mayer T; Brookman L; Nedelman J; Skerjanec A; Böhler T; Neumayer HH
    Am J Transplant; 2003 Jul; 3(7):846-54. PubMed ID: 12814476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship.
    Skerjanec A; Tedesco H; Neumayer HH; Cole E; Budde K; Hsu CH; Schmouder R
    J Clin Pharmacol; 2005 Nov; 45(11):1268-78. PubMed ID: 16239360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FTY720 mediates apoptosis-independent lymphopenia in human renal allograft recipients: different effects on CD62L+ and CCR5+ T lymphocytes.
    Böhler T; Waiser J; Schütz M; Dragun D; Neumayer HH; Budde K
    Transplantation; 2004 May; 77(9):1424-32. PubMed ID: 15167602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study.
    Mulgaonkar S; Tedesco H; Oppenheimer F; Walker R; Kunzendorf U; Russ G; Knoflach A; Patel Y; Ferguson R;
    Am J Transplant; 2006 Aug; 6(8):1848-57. PubMed ID: 16771816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus in combination with FTY720--an analysis of renal and blood parameters.
    Gallo AP; Silva LB; Franco M; Burdmann EA; Bueno V
    Int Immunopharmacol; 2006 Dec; 6(13-14):1919-24. PubMed ID: 17219691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants.
    Ettenger R; Schmouder R; Kovarik JM; Bastien MC; Hoyer PF
    Pediatr Transplant; 2011 Jun; 15(4):406-13. PubMed ID: 21585629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study.
    Tedesco-Silva H; Szakaly P; Shoker A; Sommerer C; Yoshimura N; Schena FP; Cremer M; Hmissi A; Mayer H; Lang P;
    Transplantation; 2007 Oct; 84(7):885-92. PubMed ID: 17984842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.